Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

Journal of Hepatology

Volumn 56, Issue 6, 2012, Pages 1336-1342

  Park, Joong Won ^a   Koh, Young Hwan ^a   Kim, Hyun Beom ^a   Kim, Hwi Young ^a   An, Sangbu ^a   Choi, Joon Il ^a   Woo, Sang Myung ^a   Nam, Byung Ho ^a  

^a National Cancer Center   (South Korea)

Author keywords

Concurrent treatment; Hepatocellular carcinoma; Sorafenib; TACE

Indexed keywords

DOXORUBICIN; GELFOAM; IODINATED POPPYSEED OIL; SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ASCITES; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONSTIPATION; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84862776910     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.01.006     Document Type: Article

References (34)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and T. Murray Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96 (Pubitemid 351521864)
2. H.R. Shin, E. Masuyer, J. Ferlay, and M.P. Curado Cancer in Asia - incidence rates based on data in cancer incidence in five continents IX (1998-2002) Asian Pac J Cancer Prev 11 2010 11 16
3. F.X. Bosch, J. Ribes, M. Diaz, and R. Cleries Primary liver cancer: worldwide incidence and trends Gastroenterology 127 2004 S5 S16
4. H.B. El-Serag, and A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750 (Pubitemid 29114292)
5. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
6. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, and J. Aponte Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739 (Pubitemid 34607087)
7. K.W. Park, J.W. Park, J.I. Choi, T.H. Kim, S.H. Kim, and H.S. Park Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area J Gastroenterol Hepatol 23 2008 467 473 (Pubitemid 351342066)
8. C.M. Lo, H. Ngan, W.K. Tso, C.L. Liu, C.M. Lam, and R.T. Poon Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171 (Pubitemid 34454013)
9. A.B. Benson 3rd, T.A. Abrams, E. Ben-Josef, P.M. Bloomston, J.F. Botha, and B.M. Clary NCCN clinical practice guidelines in oncology: hepatobiliary cancers J Natl Compr Canc Netw 7 2009 350 391
10. M. Omata, L.A. Lesmana, R. Tateishi, P.J. Chen, S.M. Lin, and H. Yoshida Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma Hepatol Int 4 2010 439 474
11. S. Arii, M. Sata, M. Sakamoto, M. Shimada, T. Kumada, and S. Shiina Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009) Hepatol Res 40 2010 667 685
12. K. Klcsg-Ncc Practice guidelines for management of hepatocellular carcinoma 2009 Korean J Hepatol 15 2009 391 423
13. E. Alba, C. Valls, J. Dominguez, L. Martinez, E. Escalante, and L. Llado Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation AJR Am J Roentgenol 190 2008 1341 1348 (Pubitemid 351684928)
14. X. Li, G.S. Feng, C.S. Zheng, C.K. Zhuo, and X. Liu Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level World J Gastroenterol 10 2004 2878 2882 (Pubitemid 39303010)
15. J.H. Shim, J.W. Park, J.H. Kim, M. An, S.Y. Kong, and B.H. Nam Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients Cancer Sci 99 2008 2037 2044
16. A. Sergio, C. Cristofori, R. Cardin, G. Pivetta, R. Ragazzi, and A. Baldan Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness Am J Gastroenterol 103 2008 914 921 (Pubitemid 351506379)
17. B.M. Strebel, and J.F. Dufour Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease Expert Rev Anticancer Ther 8 2008 1743 1749
18. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
19. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
20. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
21. R. Lencioni, X.P. Chen, L. Dagher, and A.P. Venook Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15 2010 42 52
22. M. Kudo Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice Int J Clin Oncol 15 2010 242 255
23. M.B. Thomas, D. Jaffe, M.M. Choti, J. Belghiti, S. Curley, and Y. Fong Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting J Clin Oncol 28 2010 3994 4005
24. H.Y. Kim, and J.W. Park Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone Dig Dis 29 2011 303 309
25. S. Ueno, G. Tanabe, K. Nuruki, M. Hamanoue, Y. Komorizono, and M. Oketani Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis Hepatol Res 24 2002 395 403 (Pubitemid 36002129)
26. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
27. J.W. Park, K.W. Park, S.H. Cho, H.S. Park, W.J. Lee, and D.H. Lee Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study Am J Gastroenterol 100 2005 2194 2200
28. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
29. H.Y. Kim, J.W. Park, H.K. Park, S.M. Woo, J.I. Choi, and H.-B. Kim Outcome of transarterial chemoembolization in Korean patients with hepatocellular carcinoma: reference for a prospective combination study with molecular targeted agents Hepatology 52 2010 1183A
30. M. Kudo, K. Imanaka, N. Chida, K. Nakachi, W.Y. Tak, and T. Takayama Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma Eur J Cancer 47 2011 2117 2127
31. J.F. Dufour, H. Hoppe, M.H. Heim, B. Helbling, O. Maurhofer, and Z. Szucs-Farkas Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study Oncologist 15 2010 1198 1204
32. J. Lammer, K. Malagari, T. Vogl, F. Pilleul, A. Denys, and A. Watkinson Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
33. T.M. Pawlik, D.K. Reyes, D. Cosgrove, I.R. Kamel, N. Bhagat, and J.F. Geschwind Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma J Clin Oncol 29 2011 3960 3967
34. J.H. Shim, J.W. Park, J.I. Choi, B.J. Park, and C.M. Kim Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area J Cancer Res Clin Oncol 135 2009 617 625